Singapore: Allied Healthcare has achieved positive results in the study of Adapt-treated tissue as a bioprosthetic substitute for abdominal hernia repairs as well as pelvic floor reconstructions in an experimental model. In the study the Adapt tissue was superior or equal to the comparative synthetic implant.

No macroscopic evidence of calcification or visible immunological responses was found in the explanted Adapt-treated tissue in both the hernia and pelvic floor reconstructions at the end of the study period.

"These results are significant in building further revenue in areas outside of CardioCel for cardiovascular applications. With combined markets of over $750 million we are excited about the future prospects of building significant revenue for our group and bringing to market innovative regenerative tissue products developed from our Regenerative Medicine Division said Mr Lee Rodne, MD, Allied Healthcare Group.

Assessment of the physical properties of the explanted Adapt-treated tissues after six months demonstrated a better outcome than the control in that the Adapt-treated tissue remained stable and intact without any significant deformation of the original shape (configuration) and size (dimensions) compared to synthetic meshes which tended to contract and shrink.

Recently Allied announced that its lead regenerative tissue product CardioCel, made using the Adapt process, showed significant tissue regeneration post implantation in cardiovascular repair.